These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24727596)

  • 41. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL
    Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL; Evans M; Toft AD; Jenkins-Jones S; Poole CD; Currie CJ
    Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF; Dornhorst A; Sreenan S;
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G; Caputo S; De Pergola G; Di Carlo A; Grassi G; Lapolla A; Pata P; Solerte SB; Zaccardi F
    Expert Opin Pharmacother; 2011 Nov; 12(16):2449-55. PubMed ID: 21988213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe hypoglycemia and ketoacidosis over one year in Italian pediatric population with type 1 diabetes mellitus: a multicenter retrospective observational study.
    Cherubini V; Pintaudi B; Rossi MC; Lucisano G; Pellegrini F; Chiumello G; Frongia AP; Monciotti C; Patera IP; Toni S; Zucchini S; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2014 May; 24(5):538-46. PubMed ID: 24418381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
    Bae JP; Duan R; Fu H; Hoogwerf BJ
    Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoglycemia and the hypoglycemic unawareness syndrome.
    Hirsch IB
    Diabetes Technol Ther; 2000; 2 Suppl 1():S81-7. PubMed ID: 11469638
    [No Abstract]   [Full Text] [Related]  

  • 50. Insulin analogues and severe hypoglycaemia in type 1 diabetes.
    Kristensen PL; Hansen LS; Jespersen MJ; Pedersen-Bjergaard U; Beck-Nielsen H; Christiansen JS; Nørgaard K; Perrild H; Parving HH; Thorsteinsson B; Tarnow L
    Diabetes Res Clin Pract; 2012 Apr; 96(1):17-23. PubMed ID: 22136722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiology and risk factors of hypoglycemia in subjects with type 1 diabetes in Brazil: a cross-sectional, multicenter study.
    de Souza ABC; Correa-Giannella MLC; Gomes MB; Negrato CA; Nery M
    Arch Endocrinol Metab; 2022 Nov; 66(6):784-791. PubMed ID: 36191264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
    Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between continuous subcutaneous insulin infusion and multiple insulin injection therapy in type 1 diabetes mellitus: 18-month follow-up.
    Hissa MN; Hissa AS; Bruin VM; Fredrickson LP
    Endocr Pract; 2002; 8(6):411-6. PubMed ID: 15251830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial.
    Petit-Bibal C; Rothenbuhler A; Lucchini P; Aboumrad B; Castell AL; Le Fur S; Bougnères P
    Pediatr Diabetes; 2015 Aug; 16(5):345-53. PubMed ID: 24888575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
    Levin P; Wei W; Miao R; Ye F; Xie L; Baser O; Gill J
    Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.
    Bumbu A; Moutairou A; Matar O; Fumeron F; Velho G; Riveline JP; Gautier JF; Marre M; Roussel R; Potier L
    Diabetes Obes Metab; 2018 May; 20(5):1289-1292. PubMed ID: 29272063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.